Evercore Inc. (EVR) Reaches $111.12 High on May, 22; Synergy Pharmaceuticals (SGYP) Sentiment Is 1.22

May 22, 2018 - By Darrin Black

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Logo

The stock of Evercore Inc. (NYSE:EVR) reached all time high today, May, 22 and still has $118.90 target or 7.00% above today’s $111.12 share price. This indicates more upside for the $4.85B company. This technical setup was reported by Barchart.com. If the $118.90 PT is reached, the company will be worth $339.22 million more. The stock increased 0.75% or $0.8236 during the last trading session, reaching $111.1236. About 58,145 shares traded. Evercore Inc. (NYSE:EVR) has risen 10.25% since May 22, 2017 and is uptrending. It has underperformed by 1.30% the S&P500.

Synergy Pharmaceuticals Inc (SGYP) investors sentiment decreased to 1.22 in Q4 2017. It’s down -0.68, from 1.9 in 2017Q3. The ratio is negative, as 67 hedge funds increased or opened new holdings, while 55 sold and decreased their stakes in Synergy Pharmaceuticals Inc. The hedge funds in our database now possess: 125.65 million shares, down from 147.06 million shares in 2017Q3. Also, the number of hedge funds holding Synergy Pharmaceuticals Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 21 Reduced: 34 Increased: 43 New Position: 24.

Since February 1, 2018, it had 0 insider purchases, and 11 insider sales for $57.18 million activity. Klurfeld Jason sold 717 shares worth $73,851. 132,578 shares were sold by Altman Roger C, worth $13.34 million on Thursday, February 1. The insider SCHLOSSTEIN RALPH sold $7.19M. SIBBALD ANDREW sold $129,612 worth of stock. On Tuesday, February 13 the insider Walsh Robert B sold $2.12M. Pensa Paul also sold $129,548 worth of Evercore Inc. (NYSE:EVR) shares. Shares for $1.81 million were sold by Arellano Ostoa Augusto.

Analysts await Evercore Inc. (NYSE:EVR) to report earnings on July, 26. They expect $1.50 earnings per share, up 41.51% or $0.44 from last year’s $1.06 per share. EVR’s profit will be $65.41M for 18.52 P/E if the $1.50 EPS becomes a reality. After $2.24 actual earnings per share reported by Evercore Inc. for the previous quarter, Wall Street now forecasts -33.04% negative EPS growth.

Among 11 analysts covering Evercore Partners (NYSE:EVR), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Evercore Partners had 29 analyst reports since September 8, 2015 according to SRatingsIntel. Nomura maintained the shares of EVR in report on Friday, November 3 with “Neutral” rating. The stock has “Neutral” rating by Goldman Sachs on Tuesday, May 23. As per Tuesday, January 9, the company rating was upgraded by UBS. The firm has “Hold” rating by Keefe Bruyette & Woods given on Wednesday, January 10. The stock of Evercore Inc. (NYSE:EVR) has “Hold” rating given on Wednesday, March 16 by Craig Hallum. The rating was maintained by Sandler O’Neill on Thursday, January 11 with “Buy”. Keefe Bruyette & Woods initiated the shares of EVR in report on Monday, March 27 with “Mkt Perform” rating. The company was maintained on Thursday, December 21 by Keefe Bruyette & Woods. The company was downgraded on Monday, November 9 by Nomura. Susquehanna maintained Evercore Inc. (NYSE:EVR) on Monday, October 12 with “Positive” rating.

Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. The company has market cap of $4.85 billion. The firm operates through two divisions, Investment Banking and Investment Management. It has a 39.69 P/E ratio. The Investment Banking segment provides advisory services on mergers, acquisitions, divestitures, leveraged buyouts, and similar corporate finance matters; capital markets advice relating to debt and equity securities; and services related to securities underwriting, private placement services, and commissions for agency equity trading services and equity research.

More notable recent Evercore Inc. (NYSE:EVR) news were published by: Themiddlemarket.com which released: “M&A daily wrap: Middleby, Taylor, United Technologies, Campbell Soup, IHS Markit, Ipreo, Blackstone” on May 21, 2018, also Seekingalpha.com with their article: “Evercore (EVR) Q1 2018 Results – Earnings Call Transcript” published on April 25, 2018, Prnewswire.com published: “David Noah to Join Evercore in July as a Senior Managing Director in the Firm’s Investment Banking Business” on May 14, 2018. More interesting news about Evercore Inc. (NYSE:EVR) were released by: Gurufocus.com and their article: “Evercore Inc (EVR) President and CEO Ralph Schlosstein Sold $18.2 million of Shares” published on May 03, 2018 as well as Prnewswire.com‘s news article titled: “Gregory Berube to Join Evercore in August as a Senior Managing Director in the Firm’s Investment Banking Business” with publication date: May 07, 2018.

Investors sentiment increased to 1.03 in Q4 2017. Its up 0.01, from 1.02 in 2017Q3. It is positive, as 18 investors sold Evercore Inc. shares while 110 reduced holdings. 42 funds opened positions while 90 raised stakes. 36.53 million shares or 1.84% more from 35.87 million shares in 2017Q3 were reported. Alpha Windward Ltd Liability invested in 0.02% or 364 shares. Jpmorgan Chase Co owns 732,325 shares. Vanguard Group Inc owns 3.35 million shares for 0.01% of their portfolio. Alliancebernstein Limited Partnership, a New York-based fund reported 83,540 shares. Invesco Limited holds 0.02% or 728,112 shares. 60 are owned by Lazard Asset Management Lc. 456,075 were reported by Fiera Capital Corporation. Millennium Management has invested 0.01% in Evercore Inc. (NYSE:EVR). State Of Wisconsin Board has invested 0.04% in Evercore Inc. (NYSE:EVR). Amalgamated Bank reported 5,634 shares. Credit Suisse Ag invested in 0.01% or 66,498 shares. Cypress Capital Lc (Wy) invested 0.02% of its portfolio in Evercore Inc. (NYSE:EVR). California-based Los Angeles Cap And Equity Rech Inc has invested 0.05% in Evercore Inc. (NYSE:EVR). Ajo L P accumulated 431,392 shares. South Dakota Investment Council has invested 0.08% in Evercore Inc. (NYSE:EVR).

Ratings analysis reveals 67% of Synergy Pharma’s analysts are positive. Out of 3 Wall Street analysts rating Synergy Pharma, 2 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. SGYP was included in 3 notes of analysts from December 23, 2016. As per Thursday, January 5, the company rating was initiated by Oppenheimer. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Friday, December 23 with “Buy” rating. The rating was downgraded by Citigroup on Thursday, April 6 to “Sell”.

It closed at $1.6 lastly. It is down 62.55% since May 22, 2017 and is downtrending. It has underperformed by 74.10% the S&P500.

Analysts await Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on August, 8. They expect $-0.16 EPS, up 51.52% or $0.17 from last year’s $-0.33 per share. After $-0.15 actual EPS reported by Synergy Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 6.67% negative EPS growth.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $394.78 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

More important recent Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) news were published by: Seekingalpha.com which released: “Synergy Pharmaceuticals Investors: Refocus Away From Management” on May 17, 2018, also Seekingalpha.com published article titled: “Synergy Pharmaceuticals: The Short Covering Has Begun”, Seekingalpha.com published: “Synergy Pharmaceuticals: Q1 Earnings Preview” on April 30, 2018. More interesting news about Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) was released by: Seekingalpha.com and their article: “Synergy Pharmaceuticals’ (SGYP) CEO Troy Hamilton on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: